The crystal structure of the kinase domain of C-terminal Src kinase (CSK) has been determined by molecular replacement, co-complexed with the protein kinase inhibitor staurosporine (crystals belong to the space group P21212 with a 44.5 A Ê , b 120.6 A Ê , c 48.3 A Ê ). The ®nal model of CSK has been re®ned to an R-factor of 19.9 % (R free 28.7 %) at 2.4 A Ê resolution. The structure consists of a small, N-terminal lobe made up mostly of a b-sheet, and a larger C-terminal lobe made up mostly of a-helices. The structure reveals atomic details of interactions with staurosporine, which binds in a deep cleft between the lobes. The polypeptide chain fold of CSK is most similar to c-Src, Hck and ®broblast growth factor receptor 1 kinase (FGFR1K) and most dissimilar to insulin receptor kinase (IRK).
Introduction
Tyrosine and serine/threonine protein kinases share several conserved motifs that confer both structural and catalytic functions (Hanks & Quinn, 1991) . All of these kinases share the same type of bi-lobal fold, however, subtle sequence and structural differences determine individual kinase characteristics such as regulation of catalytic ef®ciency and substrate binding (Yamaguchi & Hendrickson, 1996; Mohammadi et al, 1996; Hubbard, 1997) .
Src-family protein tyrosine kinases provide important links between plasma membrane events and the cell nucleus (reviewed by Courtneidge, 1994) . The C-terminal Src kinase (CSK) is a protein tyrosine kinase (PTK) which phosphorylates the Src-family kinases in vitro at a C-terminal tyrosine residue (equivalent to tyrosine 527 in C-Src). Src C-terminal tyrosine phosphorylation results in a Src enzyme conformation with low protein kinase activity due to an intramolecular association (Murphy et al., 1993; Xu et al., 1997) . Transgenic CSK gene knockout mice have neuronal tube defects and are embryonically lethal. However, cell lines from these mice have demonstrated hyperactivity of Src kinases (Imamoto & Soriano, 1993; Nada et al., 1993) . For these reasons, CSK has been viewed as an important regulator kinase keeping Src kinases inactive until cell stimulation.
CSK is expressed ubiquitously as a protein of approximately 50 kDa and shows domain structure similarity to C-Src. Like C-Src, CSK has Src homology 2 (SH2) and 3 (SH3) domains (Pawson, 1995; Cohen et al., 1995) , but lacks an N-terminal myristoylation site and phosphorylation site sequences corresponding to the autophosphorylation site and the regulatory C-terminal tail of Src. The myristoylation sequence in Src is responsible for plasma membrane location, implying that the non-myristoylated CSK is located in the cell cytoplasm. The main Src autophosphorylation site is on tyrosine 415 in protein kinase subdomain VIII (Hanks & Quinn, 1991) , which fully activates the enzyme when phosphorylated. The analogous region, also known as the regulatory loop, on CSK is a shorter sequence that contains two serine and two threonine residues, which cannot be autophosphorylated. Furthermore, no residues within this loop sequence have been shown to be phosphorylated in CSK (Courtneidge, 1994) . The role of this region in CSK is therefore unclear.
Peptides based on Src family C termini are poor CSK substrates, suggesting that, unlike other PTKs, primary amino acid sequence does not solely determine the substrate speci®city of this enzyme (Sondhi et al., 1998) . There is also evidence that Src kinases can autophosphorylate their C-terminal regulatory tails in the absence of CSK (Bougeret et al., 1994; Ruzle et al., 1994) . Moreover, optimal peptide substrates of CSK have been shown to have sequences unrelated to those found in Src kinase C termini, suggesting that there are other physiological CSK substrates and hence cellular functions yet to be identi®ed (Ruzzene et al., 1997) .
Staurosporine is a microbial alkaloid isolated from Streptomyces sp. (Omura et al., 1977) which has been shown to be a potent broad-range inhibitor competing with ATP, but not peptide substrate, for binding to protein kinases. Staurosporine has nanomolar potency against many protein kinases, but only micromolar potency against protein kinases such as casein kinase 1 (CK1), casein kinase 2 (CK2), mitogen-activated protein kinase (MAPK) and CSK (Meggio et al., 1995) . This level of selectivity has already enabled staurosporine to be used as a lead inhibitor for the design of speci®c potent protein kinase inhibitors (Toullec et al., 1991; Bit et al., 1993; Trinks et al., 1994; Buchdunger et al., 1994) .
We report here the determination of the crystal structure of the human CSK catalytic domain cocomplexed with the protein kinase inhibitor staurosporine. The structures of the serine/threonine protein kinases protein kinase A (PKA) and cyclindependent kinase 2 (CDK2) in complex with staurosporine have recently been solved (Prade et al., 1997; Lawrie et al., 1997) . Our structure demonstrates that, as with serine/threonine protein kinases, staurosporine is able to induce conformational changes in the protein tyrosine kinase catalytic site, highlighting the¯exibility of the kinase domain structure. This information will aid the understanding of protein tyrosine kinase catalytic mechanisms and the rational design of inhibitor molecules for therapeutic drug development.
Results and Discussion
Quality of the final structure
Modi®ed Escherichia coli cells were used to express the catalytic domain of human CSK (residues 172-450) which possesses PTK activity. Crystals belonging to the P21212 space group with a 44.5 A Ê , b 120.6 A Ê , c 48.3 A Ê were obtained liganded with the protein kinase inhibitor staurosporine. The asymmetric part of the unit cell contains one molecule of recombinant CSK, which, in addition to 274 CSK residues (amino acid residues 177-450 of the full-length protein), contains a fourresidue N-terminal extension and ten C-terminal residues including a hexahistidine puri®cation tag (Stu È ber et al., 1990) resulting in the total molecular mass of 32,354 Da. One CSK molecule per asymmetric part gives the solvent content of 38.1 % and the speci®c volume (Matthews, 1968) , V M , of 2.0 A Ê 3 /Da. Complete X-ray data have been collected to 2.4 A Ê resolution from¯ash-frozen crystal. A total of 30,746 individual measurements were reduced to 10,089 unique re¯ections with an overall merging R-factor of 7.5 %. Table 1 summarises the data collection statistics.
The CSK structure has been determined by molecular replacement using the coordinates of c-Src kinase (Xu et al., 1997) . The best molecular replacement solution was obtained with the C-terminal lobe fragment of the c-Src catalytic domain. The smaller N-terminal lobe subdomain or the fulllength catalytic domain did not give a clear solution. The structure has been re®ned to an R-factor of 19.9 % for all data in the resolution range 30-2.4 A Ê (R free 28.7 %; Table 2 ). The ®nal electron density maps allowed the positioning of all residues except 14 N-terminal residues, 12 C-terminal residues and loop residues 228 and 229 (78 and 79), 259 and 260 (114 and 115) and 336 to 347 (188 to 199) , respectively (PKA numbering in parentheses). These regions are presumably highly¯exible and therefore are not clearly de®ned in the electron density maps. Loop region 336-347 contains the regulatory loop which is known to undergo signi®-cant conformational change (Marshall, 1994 ). The ®nal model contains 2092 atoms including 152 water molecules and 35 staurosporine atoms. In addition, the model contains 48 atoms that belong to disordered side-chains. These atoms were omitted from the re®nement and have been set the occupancy of 0.0. The dispersion precision indicator based on the R free value (Cruickshink, 1996; gives an estimate of r.m.s. error in coordinates of 0.34 A Ê . None of the non-glycine residues lies outside the allowed regions of the Ramachandran plot (Ramakrishan & Ramachandran, 1965; Laskowski et al., 1993) . Figure 1 shows electron density maps corresponding to the ®nal model.
The CSK used in this structural determination was not phosphorylated at residue 304, a previously reported putative in vitro autophosphorylation site (Joukov et al., 1997) . However, the enzyme was still catalytically active (data not shown), using published substrates (Bergman et al., 1995) .
Structure description
The structure of CSK uses the established nomenclature for protein kinase secondary-structural elements (Knighton et al., 1991; Hubbard et al., 1994) as shown in Figure 2 . The N-terminal lobe comprises a curled b-sheet of ®ve anti-parallel b-strands (b1-b5) and one a-helix (aC) positioned between the b3 and b4 strands. The C-terminal lobe comprises two b-strands (b7 and b8) and seven a-helices (aD, aE, aEF, aF, aG, aH and aI). CSK is similar in structure to the previously reported protein tyrosine kinases IRK (Hubbard et al., 1994) , Hck (Sicheri et al., 1997) , c-Src (Xu et al., 1997) , FGFRK (Mohammadi et al., 1996) and Lck Table 2 . Data collection and re®nement summary Crystallographic R-factor, R free AE kF o j À jF c k/AE jF o j. (Yamaguchi & Hendrickson, 1996) . A structurebased sequence alignment of CSK and other published protein kinase structures is shown in Figure 3 .
The staurosporine molecule binds between the N-terminal and C-terminal lobes in a hydrophobic cleft lined by the residues Val249, Leu321, Met269, Phe333, Ala220, Ile201, Gly202, Val209, Gly204 and Gly272 (Figure 1 and see Figure 5 (a)). Interactions of staurosporine with protein include hydrogen bonds between Met269, Glu267 and Arg318 and hydrophobic interactions with the cleft residue side-chains.
Detailed comparisons with other protein tyrosine kinases
CSK is most similar in terms of topology to c-Src, Hck and FGFRK by C a -C a superposition (Kabsch & Sander, 1983; Sutcliffe et al., 1987;  Table 3 ). Table 3 , which illustrates the differences in C a geometry, also includes the two non-tyrosine kinases PKA and cyclin-dependent kinase 2 as they both have been solved as co-complexes containing staurosporine. Of the published tyrosine kinases, CSK is most dissimilar to insulin receptor kinase in terms of r.m.s. deviation of C a atoms in the C-terminal lobe (Figure 4 ). These differences are mainly due to an eight amino acid residue loop deletion in CSK between residues 283 and 284 with respect to the insulin receptor kinase (residues 1094 to 1101). The structure-determined region of the regulatory loop also diverges signi®cantly in CSK at positions 331 to 335 (1149 to 1154 in the insulin receptor kinase). In terms of structural topology, the N-terminal ATP-binding lobe of CSK is most like the Hck PTK, but a comparison of residues around the ATP-binding site reveals several sequence and structural variations (Figure 3 ).
There is no clearly de®ned electron density for the regulatory loop residues 336-347, suggesting that this loop is¯exible in the absence of substrate. The visible electron density ends of the regulatory loop, residues 335 and 348, are situated at the opposite sides of the cavity between the N-terminal and the C-terminal lobes and point into the outer surface of the cavity. Therefore, it is likely that the Figure 3 . Sequence alignment of the human CSK kinase domain (residues 187-450), human c-Src (residues 259-527; Xu et al., 1997) , human Lck (residues 259-501; Yamaguchi & Hendrickson, 1996) , human Hck (residues 267-527; Sicheri et al., 1997) , human FGFR1 K (residues 470-762; Mohammadi et al., 1996) , IRK (residues 988-1274; Hubbard et al., 1994) , human CDK2 (residues 1-266; Lawrie et al., 1997) and bovine PKA (residues 35-303; Prade et al., 1997) . Secondary-structure elements are indicated as shown in Figure 2 (a-helices are indicated by purple, b-strands by yellow, the b-bulge by green). Conserved residues are shown red. *, Putative CSK phosphorylation sites; Á Á Á Á Á Á", regulatory loop sequence; &, catalytic loop; *, differences in sequence at the same position within the ATP-binding pocket; !, differences in residue position at the same sequence position in the ATP-binding pocket. Sequence identity calculated as a percentage similarity of the catalytic domains (both N-terminal (Nter) and C-terminal (Cter) subdomains). The C a -C a ®tting was performed after an initial sequence alignment of each kinase to CSK and superposition. Fitting then followed this on C a atoms until the root-mean-square deviations converged for each structure with respect to CSK. The N-terminal and C-terminal lobes were ®tted using the residue range indicated in the Table (numbering as from the original PDB entries).
substrate binds this unphosphorylated form of the enzyme by an induced-®t mechanism where the regulatory loop adopts the necessary conformation upon substrate binding. There are putative phosphorylation sites in the loop sequence (Figure 3) . Although there is not yet evidence for phosphorylation of these serine/threonine residues it is tempting to speculate that phosphorylation of any of these amino acid residues could allow loop stabilisation via electrostatic interactions with the enzyme. Indeed, the regulatory loop of active PKA is the same size as the CSK loop and is phosphorylated on Thrl97. This phosphorylated residue allows loop stabilisation by making several contacts with the enzyme structure (Zheng, 1993) . Moreover, the visible density corresponding to the start and the end of the CSK regulatory loop closely mirrors the positions of the analogous residues in active PKA co-complexed with staurosporine (Prade et al., 1997) .
The polypeptide chain fold in all published protein kinase structures is similar, with the largest differences being in loop regions. However, the relative orientation of the N-terminal and the C-terminal lobes in these enzymes shows considerable variability. CSK lobe orientation shows most similarity to the other staurosporine co-complexed protein serine/threonine kinase structures of CDK2 and PKA (Lawrie et al., 1997; Prade et al., 1997) . The relative lobe rotation is open approximately 8 with respect to the closed, active PKA structure . This ®gure is less than the 17
obtained for the open, inactive ERK2 enzyme (Zhang et al., 1994) .
The binding of staurosporine
Micromolar concentrations of staurosporine are necessary to reduce CSK enzyme activity by 50 % (IC 50 ) whereas only nanomolar concentrations are required for the inhibition of serine/threonine kinases such as PKA and CDK2 (Meggio et al., 1995; Lawrie et al., 1997) . Figure 1 represents the electron density for the staurosporine-binding site. The position of staurosporine in the hydrophobic N-terminal ATP-binding pocket of CSK almost exactly matches the relative position of the inhibitor in the PKA structure described by Prade et al. 1997 ; Figure 5(a) ). However, there are clear differences in inhibitor-enzyme contact that would explain the three orders of magnitude staurosporine-binding difference between the enzymes. Polar hydrogen atoms were added to both the CSK and PKA structures and optimised to convergence. The N31 methylamino, group of staurosporine was predicted to be protonated at physiological pH. Single CHARMm (v23.2) point energy calculations were then made for each system using a dielectric constant of either 4 or 10. Energy-difference calculations for the interaction of protonated staurosporine with PKA and CSK gave a ÁE difference of 7.3 kcal/mol at a dielectric constant of 4, and 1.9 at a dielectric constant of 10. The energy difference range of 1.9 to 7.3 kcal/mol is enough to explain three orders of magnitude difference in binding and thus the IC 50 difference between the enzymes (Murcko & Murcko, 1995; Bo È hm & Klebe, 1996) .
One of the contributions to the above interaction energy calculations is the number of inhibitorenzyme hydrogen bonds. Staurosporine can only make three hydrogen-bond contacts with CSK as opposed to the four possible in both PKA and CDK2 (Figure 5(b) ). These are the lactam carbonyl group O30 to the backbone amide group of Met269 (equivalent to Val123 in PKA), the N19 lactam ring amide hydrogen bond donating to the Glu267 backbone carbonyl group (equivalent to Glu121 in PKA) and the methylamino, N31 hydrogen bond donating to the Arg318 backbone carbonyl group (equivalent to Glu170 in PKA). The missing hydrogen bond would be formed between N31 and the side-chain of Glu127 in PKA and Asp86 in CDK2. N31 protonation would also mean there was a charge-charge interaction with these side-chains. Such a bond is not formed in CSK as the equivalent residue is Ser273, which is hydrogen bonded to the amide backbone of Asp276. Other protein kinases such as CK1, CK2 and MAPK, which are not potently inhibited by staurosporine, also have a serine residue in the position analogous to Ser273 suggesting a general reason for a potency difference of staurosporine between protein kinases.
There are clear differences in the relative positions of equivalent residues between CSK and other published protein tyrosine kinases. Speci®-cally, there is a marked shift in the backbone and side-chains of conserved Asp332 and Phe333 in the magnesium ion-binding loop of CSK. It is not possible to say unequivocally that these residues would mirror the positions shown in other structures in the absence of staurosporine until a non-inhibitorcomplexed CSK structure has been solved. However, it is a reasonable assumption based on the loop's functional role in co-ordinating the phosphate groups of ATP. Furthermore, similar shifts of these residues have been observed on staurosporine binding to PKA (Prade et al., 1997) . These residue shifts demonstrate that the binding of staurosporine to CSK is of an induced-®t type, altering the ATP-binding pocket in order to bind and inhibit the enzyme.
Aberrant activation and/or regulation of endogenous protein kinases have been implicated in many disease states such as oncology, autoimmunity and allergy (Bradshaw et al., 1993; Levitzki & Gazit, 1995) . Furthermore, invading pathogens also have their own protein kinases that play a role in pathogen survival and replication. Thus, the design of small molecular mass inhibitors of these enzymes has assumed major importance for the development of many therapeutic drugs. Development of novel protein kinase inhibitors will be accelerated by structural information on inhibitor/ protein kinase interaction. Success with the CSKstaurosporine structure provides a step towards Figure 5 . (a) Superposition of the bovine PKA and CSK ATP-binding, sites. C a trace of key residues within 10 A Ê of the staurosporine inhibitor. The CSK is shown in green and the PKA (1stc.pdb) in blue. Homologous residues (same position in space and in sequence) are coloured red. The residue numbers given are for conserved CSK residues. (b) Two-dimensional schematic representation of the close contact residues around staurosporine in the CSK structure, produced using IDRAW. Hydrogen-bonding residues shown as lines with the hydrogen bonds annotated as a broken line. Residues are also shown that are within a distance of 3.9 A Ê (circle). the more rational design of protein kinase inhibitors that could be used for disease therapy.
Stability of the catalytic domain
Previous modelling studies of the CSK catalytic domain have suggested that there is structure-stabilising Tyr304 to Arg244 hydrogen bonding, maintained in both the open and closed enzyme forms, that bridges helix C to helix E (Joukov et al., 1997) . We observe several important water molecules that form lobe-bridging hydrogen bonds, most notably water molecules 11, 61 and 84. These are capable of forming several hydrogen bonds and stabilising the junction between the lobes (Figure 6 ). Water61 forms a hydrogen bond with the Ser246 backbone carbonyl oxygen atom and the Lys329 side-chain NZ. Water84 can form a hydrogen bond with the Glu267 OE1 side-chain carboxyl oxygen atom, Leu248 backbone carbonyl oxygen atom, His245 backbone carbonyl oxygen atom, Lys329 side-chain NZ and the Ser246 backbone carbonyl oxygen atom. Water 11 can form a hydrogen bond with the Arg437 side-chain NH1 and His245 side-chain NE2.
The lobe-spanning hydrogen bonds formed between residues are Ala328 backbone O and Asn247 side-chain ND2 Val330 backbone N and Asn247 side-chain O and the previously reported Tyr304 side-chain OH and Arg244 backbone N. A salt bridge interaction is formed between the Lys329 side-chain NZ and the Glu267 side-chain OE2 (Figure 6 ). Similar hydrogen-bonding interactions are present in nearly all other tyrosine and serine/threonine kinases. In PKA, Lys329 is replaced by Gln181. In this enzyme, the Lys-Glu salt bridge is replaced by extra hydrogen-bond interactions between Gln181 and Glu121 (Glu267 in CSK), via water 2 and water 6 (1stc.pdb).
The CSK water 84 (Figure 2 ) is structurally conserved in IRK (water11), Lck (water1004) and c-Src (water1119) and is downstream from b5, the previously described hinge region location, which has been proposed to act as the fulcrum for movement between open and closed conformations (Olah et al., 1993; Prade et al., 1997) . To analyse further the relative movement of the lobes, we used structural data on insulin receptor kinase, for which the atomic coordinates are available for both the open (1irk.pdb) and closed (1ir3.pdb) conformations. A direct correlation was observed between the N-terminal C a distances to the conserved water molecule in the open and closed structures (Figure 7(a) ). This indicated that the N-terminal lobe does not undergo signi®cant change in overall shape on relative movement of the two lobes. The distance between equivalent C a atoms in the open and closed structures correlated with the mean C a distance from the conserved water molecule (Figure 7(b) ). This shows that the residues in the N-terminal lobe move a greater distance apart on opening of the lobes the further they are from the conserved water molecule These observations demonstrate that movement of the N-terminal lobe relative to the C-terminal lobe occurs around the water molecule. We therefore postulate that this water molecule (water 84 in CSK) acts as a general protein kinase molecular hinge or pivot.
Materials and Methods

Crystallisation
The cDNA encoding amino acid residues 177-450 of human CSK was obtained from human granulocyte cDNA using polymerase chain reaction (PCR) with the deoxynucleotide primers CGCGGATCCGTGGCCGCC-CAGGATGAGTTCTA and CGCGGATCCCAGGTG-CAGCTCGTGGGTMGA. The amplicon obtained was cloned directly into the E. coli expression vector pQE60 (Qiagen) to give the catalytic domain coding sequence, the N-terminal extension MGGS and C-terminal residues GSRSHHHHHH. CSK protein was produced from DH5a E. coli after IPTG induction and puri®ed from the cleared Figure 6 . C a trace of CSK with the key water molecules and residues at the lobe junction. Side-byside stereo image generated using the smm external display utility in Quanta97. The side-chain atom colours are: green, carbon; blue, nitrogen; red, oxygen; the solvent atoms are displayed as red spheres. Potential hydrogen bonds are displayed as broken white lines. cell lysate using FPLC (Pharmacia) cobalt chelation chromatography (Hochuli et al., 1987) .
The protein was crystallised by the hanging-drop method. Equal volumes of protein solution of 10 mg/ml including 1 mM staurosporine and well solution were combined and placed over a well containing 0.2 M magnesium chloride, 0.1 M Tris-HCl (pH 9.0) and 24 % (w/v) polyethyleneglycol (PEG) 4000. Plate-like crystals started to form after two weeks and continued to grow for up to two months to a size of 1 mm Â 1 mm Â 0.005 mm.
Data collection and processing
The crystals were characterised on a Rigaku RAXIS IIC imaging plate detector, mounted on a RU200 Rigaku. rotating anode X-ray generator operating at 50 kV and 100 mA, equipped with focusing mirrors. For the data collection, a crystal of CSK complex, with dimensions of 0.5 mm Â 0.4 mm Â 0.005 mm, was¯ash-frozen from a cryo-solution containing 5 % (v/v) glycerol, 30 % PEG 4000, 2 mg/ml CSK protein, 0.2 M MgCl 2 , 0.1 M Tris (pH 9.0), 0.5 mM staurosporine. Staurosporine was added using a 10 mM stock solution in DMSO. The data were collected with oscillations of 0.5 per image with the total rotation of crystal by 90 during the data collection. The data set was processed with the programs DENZO and SCALEPACK (Otwinowski & Minor, 1997) .
Structure determination
All crystallographic calculations were performed using the CCP4 program package (Collaborative Computational Project, Number 4, 1994) . Molecular replacement calculations were performed with AMoRe (Navaza, 1994) using human c-Src kinase coordinates for the C-terminal lobe of the catalytic domain (Xu et al., 1997) . The rotation function was calculated with the radius of integration sphere of 20 A Ê in the resolution range 10-3.5 A Ê . The rotation peak was at the 19.8 s level with the next highest peak at 11.1s. The translation solution had correlation (C AE(jF o j À hjF o ji)(jF c j À hjF c ji)/ (AE(jF o j À hjF o ji) 2 AE(jF c j À hjF c ji) 2 ) 1/2 of 28.1 % and R-factor (R AE kF o j À jF c k/AEjF o j) of 51.6 % at 3.5 A Ê resolution. After rigid body re®nement in the resolution range 10-2.7 A Ê the correlation was 46.0 % and the R-factor was 51.3 %.
Re®nement was conducted using the maximum likelihood approach as implemented in REFMAC . At the start of the re®nement the R-factor was 55.5 % for data between 30 and 2.4 A Ê . Model building was performed using the program XFIT (T. Old®eld, unpublished) as implemented in QUANTA (Molecular Simulations). After several re®nement rounds, when the R-factor dropped to 41.1 % (R free 48.6 %), the difference density maps indicated the positions for the staurosporine molecule and for some of the N-terminal lobe residues. During a further few rounds of re®nement, each followed by model rebuilding, a model was built which contained most of the N-terminal lobe. The validity of each rebuilding step of the N-terminal domain was monitored by the R free (Bru È nger, 1992) which was calculated using 1007 re¯ec-tions (10 % of the total) left out of re®nement. At the next stage, water molecules were added gradually in sets of ®ve using the program ARP (Lamzin & Wilson, 1993) followed each time by three cycles of re®nement. The structure has been further re®ned to the crystallographic R-factor of 19.9 % (R free 28.7 %) at 2.4 A Ê resolution. Geometric restraints for staurosporine, which were used throughout the re®nement, were generated using the staurosporine coordinates (Furusaki et al., 1982) in the Cambridge structural database (Allen & Kennard, 1993) .
Figure production
All Figures shown were produced using QUANTA 97 (Molecular Simulations Inc.), unless otherwise stated.
Protein Data Bank accession number
The structure factors and the re®ned coordinates of CSK have been deposited with the Brookhaven Protein Data Bank (Bernstein et al., 1977) ; the accession codes are R1BYGSF and 1BYG, respectively, and the release date is October 1999. Requests for the coordinates may be sent to david.williams@peptide.co.uk.
